Possible role of defibrotide in endothelial cell protection

M. Corsi, M. Parise, G. Gaja, M. E. Ferroro

Research output: Contribution to journalArticle

Abstract

Defibrotide is a single-stranded DNA fraction obtained from mammalian lung and is able to increase prostacyclin production by endothelial cells. It has profibrinolytic and antithrombotic properties, and we have successfully used it as an antiischaemic drug in many in-vivo experimental models. In fact, we showed that defibrotide treatment significantly protected rat heart, kidney and liver from ischaemia and postischaemic reperfusion injury. In rats treated with defibrotide, the functionality and metabolic activity of ischaemic organs were significantly protected from impairment as compared to controls treated only with the vehicle of the drug. In the present work we evaluated all our results, together with those of others, in order to hypothesize the mechanism of action of the drug. We postulated that the prominent function of defibrotide is to inhibit platelet and leukocyte adhesion to endothelial cells. This may depend on reduced cell activation possibly following drug interaction with adenosine receptors. Defibrotide could also favour endothelial-cell function through binding with haemoglobin: such binding permits oxygen release and preservation of endothelium-derived relaxing factor. Moreover, prostacyclin production by endothelial cells is responsible for many drug activities and also limits superoxide radical generation.

Original languageEnglish
Pages (from-to)157-161
Number of pages5
JournalInternational Journal of Tissue Reactions
Volume15
Issue number4
Publication statusPublished - 1993

Fingerprint

Cytoprotection
Endothelial Cells
Epoprostenol
Pharmaceutical Preparations
Endothelium-Dependent Relaxing Factors
Purinergic P1 Receptors
Single-Stranded DNA
Reperfusion Injury
Drug Interactions
Superoxides
Hemoglobins
Leukocytes
Theoretical Models
Blood Platelets
defibrotide
Oxygen
Kidney
Lung
Liver

ASJC Scopus subject areas

  • Cell Biology
  • Physiology

Cite this

Possible role of defibrotide in endothelial cell protection. / Corsi, M.; Parise, M.; Gaja, G.; Ferroro, M. E.

In: International Journal of Tissue Reactions, Vol. 15, No. 4, 1993, p. 157-161.

Research output: Contribution to journalArticle

Corsi, M, Parise, M, Gaja, G & Ferroro, ME 1993, 'Possible role of defibrotide in endothelial cell protection', International Journal of Tissue Reactions, vol. 15, no. 4, pp. 157-161.
Corsi, M. ; Parise, M. ; Gaja, G. ; Ferroro, M. E. / Possible role of defibrotide in endothelial cell protection. In: International Journal of Tissue Reactions. 1993 ; Vol. 15, No. 4. pp. 157-161.
@article{ed6d0bde7f48494eb88020ff80ee625b,
title = "Possible role of defibrotide in endothelial cell protection",
abstract = "Defibrotide is a single-stranded DNA fraction obtained from mammalian lung and is able to increase prostacyclin production by endothelial cells. It has profibrinolytic and antithrombotic properties, and we have successfully used it as an antiischaemic drug in many in-vivo experimental models. In fact, we showed that defibrotide treatment significantly protected rat heart, kidney and liver from ischaemia and postischaemic reperfusion injury. In rats treated with defibrotide, the functionality and metabolic activity of ischaemic organs were significantly protected from impairment as compared to controls treated only with the vehicle of the drug. In the present work we evaluated all our results, together with those of others, in order to hypothesize the mechanism of action of the drug. We postulated that the prominent function of defibrotide is to inhibit platelet and leukocyte adhesion to endothelial cells. This may depend on reduced cell activation possibly following drug interaction with adenosine receptors. Defibrotide could also favour endothelial-cell function through binding with haemoglobin: such binding permits oxygen release and preservation of endothelium-derived relaxing factor. Moreover, prostacyclin production by endothelial cells is responsible for many drug activities and also limits superoxide radical generation.",
author = "M. Corsi and M. Parise and G. Gaja and Ferroro, {M. E.}",
year = "1993",
language = "English",
volume = "15",
pages = "157--161",
journal = "International Journal of Tissue Reactions",
issn = "0250-0868",
publisher = "Bioscience Ediprint Inc.",
number = "4",

}

TY - JOUR

T1 - Possible role of defibrotide in endothelial cell protection

AU - Corsi, M.

AU - Parise, M.

AU - Gaja, G.

AU - Ferroro, M. E.

PY - 1993

Y1 - 1993

N2 - Defibrotide is a single-stranded DNA fraction obtained from mammalian lung and is able to increase prostacyclin production by endothelial cells. It has profibrinolytic and antithrombotic properties, and we have successfully used it as an antiischaemic drug in many in-vivo experimental models. In fact, we showed that defibrotide treatment significantly protected rat heart, kidney and liver from ischaemia and postischaemic reperfusion injury. In rats treated with defibrotide, the functionality and metabolic activity of ischaemic organs were significantly protected from impairment as compared to controls treated only with the vehicle of the drug. In the present work we evaluated all our results, together with those of others, in order to hypothesize the mechanism of action of the drug. We postulated that the prominent function of defibrotide is to inhibit platelet and leukocyte adhesion to endothelial cells. This may depend on reduced cell activation possibly following drug interaction with adenosine receptors. Defibrotide could also favour endothelial-cell function through binding with haemoglobin: such binding permits oxygen release and preservation of endothelium-derived relaxing factor. Moreover, prostacyclin production by endothelial cells is responsible for many drug activities and also limits superoxide radical generation.

AB - Defibrotide is a single-stranded DNA fraction obtained from mammalian lung and is able to increase prostacyclin production by endothelial cells. It has profibrinolytic and antithrombotic properties, and we have successfully used it as an antiischaemic drug in many in-vivo experimental models. In fact, we showed that defibrotide treatment significantly protected rat heart, kidney and liver from ischaemia and postischaemic reperfusion injury. In rats treated with defibrotide, the functionality and metabolic activity of ischaemic organs were significantly protected from impairment as compared to controls treated only with the vehicle of the drug. In the present work we evaluated all our results, together with those of others, in order to hypothesize the mechanism of action of the drug. We postulated that the prominent function of defibrotide is to inhibit platelet and leukocyte adhesion to endothelial cells. This may depend on reduced cell activation possibly following drug interaction with adenosine receptors. Defibrotide could also favour endothelial-cell function through binding with haemoglobin: such binding permits oxygen release and preservation of endothelium-derived relaxing factor. Moreover, prostacyclin production by endothelial cells is responsible for many drug activities and also limits superoxide radical generation.

UR - http://www.scopus.com/inward/record.url?scp=0027739661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027739661&partnerID=8YFLogxK

M3 - Article

C2 - 8188455

AN - SCOPUS:0027739661

VL - 15

SP - 157

EP - 161

JO - International Journal of Tissue Reactions

JF - International Journal of Tissue Reactions

SN - 0250-0868

IS - 4

ER -